Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Classical hematology 1

Conditions

Myelodysplastic Syndromes 4Leukemia, Myelomonocytic, Chronic 3Leukemia, Myeloid, Acute 3Primary Myelofibrosis 2Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Myeloproliferative Disorders 2Myelodysplastic-Myeloproliferative Diseases 2Multiple Myeloma 2Lymphoma, Non-Hodgkin 2Leukemia, Myelogenous, Chronic, BCR-ABL Positive 2Leukemia, Lymphocytic, Chronic, B-Cell 2Hodgkin Disease 2Hematologic Neoplasms 2Anemia, Refractory, with Excess of Blasts 2Thrombocytosis 1Thrombocythemia, Essential 1Prostatic Neoplasms 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Polycythemia Vera 1Pancreatic Neoplasms 1Neoplastic Syndromes, Hereditary 1Neoplasm Metastasis 1Leukemia, Myeloid, Chronic-Phase 1Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative 1Leukemia, Myeloid, Accelerated Phase 1Cytopenia 1Congenital Bone Marrow Failure Syndromes 1Clonal Cytopenia of Undetermined Significance 1Breast Neoplasms 1Bone Marrow Failure Disorders 1

Interventions

enasidenib 1canakinumab 1X-Rays 1Specimen Handling 1Biopsy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Clonal Cytopenia of Undetermined Significance × Specimen Handling × Classical hematology × Clear all
NCT05641831 2026-01-02

Canakinumab for the Prevention of Progression to Cancer in Patients With Clonal Cytopenias of Unknown Significance, IMPACT Study

Ohio State University Comprehensive Cancer Center

Phase 2 Recruiting
110 enrolled
Classical hematology

Clonal Cytopenia of Undetermined Significance

Data powered by HemOnc (CC BY 4.0) Colophon âš¡